Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 3. Rapid correction of low vitamin D status in nursing home residents 4. 2008 Exclusive Survey—Earnings: Good news for primary care income 5. Medicare pay-for-reporting effort draws fire from frustrated doctors
Your Article Summary
See Latest ArticlesRosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet, 06/23/09
Home PD et al. – Addition of rosiglitazone to glucose-lowering therapy in type 2 diabetes pts is confirmed to increase the risk of heart failure and of some fractures, mainly in women. Data are inconclusive for effects on myocardial infarction; howver, rosiglitazone does not increase risk of overall cardiovascular morbidity or mortality vs standard glucose-lowering drugs.
Methods- Study of cardiovascular outcomes after rosiglitazone addition to either metformin or sulfonylurea vs combination of the 2 over 5-7-yr follow-up
- Comparative safety assessment
- Multi-center, open-label trial of 4447 type 2 diabetes pts on metformin or sulfonylurea monotherapy with mean hemoglobin A1c (HbA1c) of 7.9%
- Randomization to addition of rosiglitazone (2220 pts) or combination of metformin and sulfonylurea (active control group, 2227)
- Primary endpoint: cardiovascular hospitalization or cardiovascular death
- During mean 5.5-yr follow-up, primary outcome met by 321 rosiglitazone pts and 323 active controls, meeting non-inferiority criterion
- Heart failure causing admission to hospital or death in 61 people in rosiglitazone group and 29 in active control group
- Upper and distal lower limb fracture rates increased mainly in female rosiglitazone pts
- Mean HbA1c lower in rosiglitazone vs control group at 5 yrs
Related Articles
Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial)
Diabetes Care, 10/14/09
Relevance Score: 88%
Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
Hepatology, 11/02/09
Relevance Score: 87%
Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09
Relevance Score: 87%
Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone
Cardiovascular Drug Reviews, 11/17/09
Relevance Score: 85%
Stretch Reduces Nephrin Expression via an Angiotensin II-AT1-dependent Mechanism in Human Podocytes: Effect of Rosiglitazone
American Journal of Physiology: Renal Physiology, 11/17/09
Relevance Score: 85%
Today in Diabetes...keeping you current
Receive free subspecialty "5-minute updates" via email
Resistance training for obese, type 2 diabetic adults: a review of the evidence
Obesity Reviews, 12/15/09
The DAFNE Collaborative. Experiences of developing a nationally delivered evidence-based, quality-assured programme for people with type 1 diabetes
Practical Diabetes International, 12/15/09
Efficacy of insulin lispro in pregnancies complicated with pregestational diabetes mellitus
Practical Diabetes International, 12/15/09
Today in Pharmacology/kinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
The role of flow-mediated dilatation in the evaluation and development of antiatherosclerotic drugs
Current Opinion in Lipidology, 12/15/09
Thiazolidinediones and the liver in humans
Current Opinion in Lipidology, 12/15/09
Effect of Obesity on Platelet Reactivity and Response to Low-Dose Aspirin
Preventive Cardiology, 12/15/09
Sponsor
Article Search
Sponsor
Sponsor